The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Bisphosphonates: Mode of Action and Pharmacology
Abstract
The profound effects of the bisphosphonates on calcium metabolism were discovered over 30 years ago, and they are now well established as the major drugs used for the treatment of bone diseases associated with excessive resorption. Their principal uses are for Paget disease of bone, myeloma, bone metastases, and osteoporosis in adults, but there has been increasing and successful application in pediatric bone diseases, notably osteogenesis imperfecta. Bisphosphonates are structural analogues of inorganic pyrophosphate but are resistant to enzymatic and chemical breakdown. Bisphosphonates inhibit bone resorption by selective adsorption to mineral surfaces and subsequent internalization by bone-resorbing osteoclasts where they interfere with various biochemical processes. The simpler, non–nitrogen-containing bisphosphonates (eg, clodronate and etidronate) can be metabolically incorporated into nonhydrolysable analogues of adenosine triphosphate (ATP) that may inhibit ATP-dependent intracellular enzymes. In contrast, the more potent, nitrogen-containing bisphosphonates (eg, pamidronate, alendronate, risedronate, ibandronate, and zoledronate) inhibit a key enzyme, farnesyl pyrophosphate synthase, in the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small guanosine triphosphate (GTP)-binding proteins (which are also GTPases) such as Rab, Rho, and Rac. The inhibition of protein prenylation and the disruption of the function of these key regulatory proteins explains the loss of osteoclast activity. The recently elucidated crystal structure of farnesyl diphosphate reveals how bisphosphonates bind to and inhibit at the active site via their critical nitrogen atoms. Although bisphosphonates are now established as an important class of drugs for the treatment of many bone diseases, there is new knowledge about how they work and the subtle but potentially important differences that exist between individual bisphosphonates. Understanding these may help to explain differences in potency, onset and duration of action, and clinical effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rho GTPases and the Actin Cytoskeleton
Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,140
Ridley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling
Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90164-8 · Cited by 3,652
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 1,743
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Self-citationEfficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta
Glorieux, F. H., Bishop, N. J., Plotkin, H., Chabot, G., Lanoue, G., & Travers, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391402 · Cited by 1,015
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862
Self-citationReduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Fleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Osteonecrosis of the Jaw and Bisphosphonates
(2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530120 · Cited by 744
Garnero, P. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.6.1693 · Cited by 707
Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C., & Burr, D. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.613 · Cited by 688
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370603 · Cited by 685
Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Self-citationFrancis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
Kavanagh, K. L., Guo, K., Dunford, J. E., Wu, X., Knapp, S., Ebetino, F. H., Rogers, M. J., Russell, R. G. G., & Oppermann, U. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601643103 · Cited by 536
Self-citationChavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523
Effect of Pyrophosphate on Hydroxyapatite and Its Implications in Calcium Homeostasis
FLEISCH, H., RUSSELL, R. G. G., & STRAUMANN, F. (1966) · Nature · doi:10.1038/212901a0 · Cited by 517
Self-citationSchenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Self-citationBisphosphonates in Bone Disease: From the Laboratory to the Patient
Fleisch, H. A. (1995) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 472
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 446
Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase
Fleish, H., & Neuman, W. F. (1961) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1961.200.6.1296 · Cited by 444
Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease
Reid, I. R., Miller, P., Lyles, K., Fraser, W., Brown, J. P., Saidi, Y., Mesenbrink, P., Su, G., Pak, J., Zelenakas, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044241 · Cited by 439
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Self-citationPreclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Self-citationRegulation of Osteoclast Function
Suda, T., Nakamura, I., Jimi, E., & Takahashi, N. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.869 · Cited by 408
Bisphosphonates: Preclinical Review
Green, J. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-3 · Cited by 405
The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
Jung, A., Bisaz, S., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547227 · Cited by 381
Rab GTPases in vesicular transport
Zerial, M., & Stenmark, H. (1993) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(93)90130-i · Cited by 381
Adverse Effects of Bisphosphonates: A Comparative Review
Adami, S., & Zamberlan, N. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00003 · Cited by 377
Bisphosphonates for breast cancer
Pavlakis, N., & Stockler, M. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474 · Cited by 360
INTERMITTENT ETIDRONATE THERAPY TO PREVENT CORTICOSTEROID- INDUCED OSTEOPOROSIS
Dachi, J. O. D. A., Ensen, W. I. G. B., Acques, J., Rown, B., Anley, D. A. H., Osse, R. O. J., Endler, D. A. L. K., Entle, B. R. L., Lszynski, W. O. O., Ouis, L., et al. (1997) · Cited by 360
Hughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357
Self-citationDempster, D., Lindsay, R., Dempster, & Lindsay (1993) · The Lancet · doi:10.1016/0140-6736(93)90570-7 · Cited by 356
Protein Prenylation: a Mediator of Protein-Protein Interactions
Marshall, C. J. (1993) · Science · doi:10.1126/science.8456312 · Cited by 350
Isolation from urine of pyrophosphate, a calcification inhibitor
Fleisch, H., & Bisaz, S. (1962) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1962.203.4.671 · Cited by 349
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Self-citationBody, J. J., Diel, I. J., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., Tripathy, D., & Bergstrom, B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601663 · Cited by 336
Lehenkari, P. P., Kellinsalmi, M., Näpänkangas, J. P., Ylitalo, K. V., Mönkkönen, J., Rogers, M. J., Azhayev, A., Väänänen, H. K., & Hassinen, I. E. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12222-5 · Cited by 333
Lai, K.-A. (2005) · The Journal of Bone and Joint Surgery (American) · doi:10.2106/jbjs.d.02959 · Cited by 332
Fleisch, H. A., Russell, R. G. G., Bisaz, S., Mühlbauer, R. C., & Williams, D. A. (1970) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1970.tb00591.x · Cited by 325
Self-citationSchenk, R., Eggli, P., Fleisch, H., & Rosini, S. (1986) · Calcified Tissue International · doi:10.1007/bf02555748 · Cited by 315
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Carano, A., Teitelbaum, S. L., Konsek, J. D., Schlesinger, P. H., & Blair, H. C. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114459 · Cited by 314
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306
Amin, D., Cornell, S., Gustafson, S., Needle, S., Ullrich, J., Bilder, G., & Perrone, M. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41388-4 · Cited by 281
The Management of Paget's Disease of Bone
Delmas, P. D., & Meunier, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360807 · Cited by 277
Luckman, S. P., Coxon, F. P., Ebetino, F. H., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1668 · Cited by 272
Self-citationFrith, J. C., M�nkk�nen, J., Auriola, S., M�nkk�nen, H., & Rogers, M. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e · Cited by 268
Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy
Sato, M., & Grasser, W. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050107 · Cited by 264
Comparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones
Masarachia, P., Weinreb, M., Balena, R., & Rodan, G. A. (1996) · Bone · doi:10.1016/8756-3282(96)00182-2 · Cited by 248
Bisphosphonates for breast cancer
Pavlakis, N., Schmidt, R. L., & Stockler, M. R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub2 · Cited by 244
Long-Term Safety of Bisphosphonates
Ott, S. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0057 · Cited by 241
Plotkin, L. I., Aguirre, J. I., Kousteni, S., Manolagas, S. C., & Bellido, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412817200 · Cited by 240
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239
Murakami, H., Takahashi, N., Sasaki, T., Udagawa, N., Tanaka, S., Nakamura, I., Zhang, D., Barbier, A., & Suda, T. (1995) · Bone · doi:10.1016/s8756-3282(95)00150-6 · Cited by 218
Statins Prevent Bisphosphonate-Induced γ,δ-T-Cell Proliferation and Activation In Vitro
Thompson, K., & Rogers, M. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301230 · Cited by 217
DIPHOSPHONATES AND PAGET'S DISEASE OF BONE
SMITH (1971) · The Lancet · doi:10.1016/s0140-6736(71)91447-4 · Cited by 203
COMPARISON OF THREE INTRAVENOUS BISPHOSPHONATES IN CANCER-ASSOCIATED HYPERCALCAEMIA
Ralston, S., Patel, U., Fraser, W., Gallacher, S., Dryburgh, F., Cowan, R., & Boyle, I. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91791-1 · Cited by 195
Flanagan, A. M., & Chambers, T. J. (1989) · Bone and Mineral · doi:10.1016/0169-6009(89)90021-4 · Cited by 195
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0224 · Cited by 195
Schmidt, A., Rutledge, S. J., Endo, N., Opas, E. E., Tanaka, H., Wesolowski, G., Leu, C. T., Huang, Z., Ramachandaran, C., Rodan, S. B., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.3068 · Cited by 194
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.
Fogelman, I., Bessent, R. G., Turner, J. G., Citrin, D. L., Boyle, I. T., & Greig, W. R. (1978) · PubMed · Cited by 192
Dr. Löwik, C. W. G. M., Van Der Pluijm, G., Van Der Wee-Pals, L. J. A., Van Treslong-De Groot, H. B., & Bijvoet, O. L. M. (1988) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650030210 · Cited by 191
Fleisch, H., Russell, R. G. G., Bisaz, S., Casey, P. A., & Mühlbauer, R. C. (1968) · Calcified Tissue Research · doi:10.1007/bf02065192 · Cited by 190
Self-citationSirohi, B., & Powles, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15736-x · Cited by 181
EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA
RUSSELL, R. (1965) · The Lancet · doi:10.1016/s0140-6736(65)91422-4 · Cited by 178
Self-citationDouglas, D., Graham G, R., Preston, C., Prenton, M., Duckworth, T., Kanis, J., Eric Preston, F., & Stuart Woodhead, J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91496-8 · Cited by 177
DIPHOSPHONATES IN PAGET'S DISEASE
Russell, R. G. G., Preston, C., Smith, R., Walton, R. J., & Woods, C. G. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90347-x · Cited by 177
Self-citationBoonen, S., Laan, R., Barton, I. P., & Watts, N. B. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1945-x · Cited by 177
Borah, B., Dufresne, T. E., Chmielewski, P. A., Johnson, T. D., Chines, A., & Manhart, M. D. (2004) · Bone · doi:10.1016/j.bone.2003.12.013 · Cited by 176
Sauty, A., Pecherstorfer, M., Zimmer-Roth, I., Fioroni, P., Juillerat, L., Markert, M., Ludwig, H., Leuenberger, P., Burckhardt, P., & Thiébaudi, D. (1996) · Bone · doi:10.1016/8756-3282(95)00448-3 · Cited by 176
Staal, A., Frith, J. C., French, M. H., Swartz, J., Güngör, T., Harrity, T. W., Tamasi, J., Rogers, M. J., & Feyen, J. H. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.88 · Cited by 174
Zhang, D., Udagawa, N., Nakamura, I., Murakami, H., Saito, S., Yamasaki, K., Shibasaki, Y., Morii, N., Narumiya, S., Takahashi, N., et al. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.6.2285 · Cited by 169
Mashiba, T., Mori, S., Komatsubara, S., Cao, Y., Manabe, T., Norimatsu, H., & Burr, D. B. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf03026321 · Cited by 165
Rogers, M. J. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0024-1 · Cited by 164
Borah, B., Dufresne, T. E., Chmielewski, P. A., Gross, G. J., Prenger, M. C., & Phipps, R. J. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1139 · Cited by 162
Reitsma, P. H., Bijvoet, O. L. M., Verlinden-Ooms, H., & van der Wee-Pals, L. J. A. (1980) · Calcified Tissue International · doi:10.1007/bf02408534 · Cited by 161
Bisphosphonates in breast cancer
Coleman, R. E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi162 · Cited by 158
Azuma, Y., Sato, H., Oue, Y., OKABE, K., Ohta, T., Tsuchimoto, M., & Kiyoki, M. (1995) · Bone · doi:10.1016/8756-3282(94)00035-x · Cited by 157
Martin, M., Arnold, W. D., Heath, H. T., Urbina, J. A., & Oldfield, E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1404 · Cited by 153
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
Bauss, F., & Russell, R. G. G. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1612-7 · Cited by 148
Self-citationLittle, D. G., McDonald, M. M., Bransford, R., Godfrey, C., & Amanat, N. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050712 · Cited by 145
Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study
Siris, E. S., Chines, A. A., Altman, R. D., Brown, J. P., Johnston, C. C., Lang, R., McClung, M. R., Mallette, L. E., Miller, P. D., Ryan, W. G., et al. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.6.1032 · Cited by 141
Gabelli, S. B., McLellan, J. S., Montalvetti, A., et al. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20754 · Cited by 133
Little, D. G., Peat, R. A., McEvoy, A., Williams, P. R., Smith, E. J., & Baldock, P. A. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.2016 · Cited by 131
Borah, B., Ritman, E. L., Dufresne, T. E., Jorgensen, S. M., Liu, S., Sacha, J. P., Phipps, R. J., & Turner, R. T. (2005) · Bone · doi:10.1016/j.bone.2005.03.017 · Cited by 130
Fleisch, H. A., Maerki, J., & Russell, R. G. G. (1966) · Experimental Biology and Medicine · doi:10.3181/00379727-122-31123 · Cited by 121
Self-citationInhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats.
Schibler, D., Russell, R. G. G., & Fleisch, H. A. (1968) · PubMed · Cited by 121
Self-citationBisphosphonates Are Incorporated into Adenine Nucleotides by Human Aminoacyl-tRNA Synthetase Enzymes
Rogers, M. J., Brown, R. J., Hodkin, V., Blackburn, G. M., Russell, R. G. G., & Watts, D. J. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1113 · Cited by 115
Self-citationLittle, D. G., Smith, N. C., Williams, P. R., BRIODY, J. N., Bilston, L. E., Smith, E. J., Gardiner, E. M., & Cowell, C. T. C. T. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1300 · Cited by 111
Monier‐Faugere, M., Geng, Z., Paschalis, E. P., Qi, Q., Arnala, I., Bauss, F., Boskey, A. L., & Malluche, H. H. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1768 · Cited by 106
The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+-ATPase
David, P., Nguyen, H., Barbier, A., & Baron, R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111017 · Cited by 102
Rogers, M. J., Ji, X., Russell, R. G. G., Blackburn, G. M., Williamson, M. P., Bayless, A. V., Ebetino, F. H., & Watts, D. J. (1994) · Biochemical Journal · doi:10.1042/bj3030303 · Cited by 102
Self-citationMühlbauer, R. C., Russell, R. G. G., Williams, D. A., & Fleisch, H. A. (1971) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1971.tb00640.x · Cited by 99
Self-citationThe bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats
Kurth, A. H. A., Eberhardt, C., Müller, S., Steinacker, M., Schwarz, M., & Bauss, F. (2005) · Bone · doi:10.1016/j.bone.2004.12.017 · Cited by 99
The long-term skeletal effects of EHDP in dogs
Flora, L., Hassing, G. S., Cloyd, G. G., Bevan, J. A., PARFITT, A. M., & Villanueva, A. R. (1981) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(81)90045-x · Cited by 95
Szabo, C. M., Matsumura, Y., Fukura, S., Martin, M., Sanders, J. M., Sengupta, S., Cieslak, J. A., Loftus, T. C., Lea, C. R., Lee, H.-J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010412y · Cited by 94
van Beek, E. R., Löwik, C. W. G. M., Que, I., & Papapoulos, S. E. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111016 · Cited by 94
The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes
Felix, R., Graham, R., Russell, R. G. G., & Fleisch, H. A. (1976) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(76)90291-6 · Cited by 93
Self-citationIntravenous Zoledronic Acid in Postmenopausal Women With Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J., Kaufman, J., Jaeger, P., et al. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200301000-00020 · Cited by 93
Use of cyclical etidronate and prevention of non-vertebral fractures
van Staa, T. P., Abenhaim, L., & Cooper, C. C. (1998) · Rheumatology · doi:10.1093/rheumatology/37.1.87 · Cited by 89
Bauss, F., Lalla, S., Endele, R., & Hothorn, L. A. (2002) · PubMed · Cited by 86
Zoledronic acid improves femoral head sphericity in a rat model of perthes disease
Little, D. G., McDonald, M. M., Sharpe, I. T., et al. (2005) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2004.11.015 · Cited by 83
Coukell, A. J., & Markham, A. (1998) · Drugs & Aging · doi:10.2165/00002512-199812020-00007 · Cited by 82
Trechsel, U., Stutzer, A., & Fleisch, H. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113257 · Cited by 74
Wilkinson, J. M., Eagleton, A. C., Stockley, I., Peel, N. F. A., Hamer, A. J., & Eastell, R. (2004) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2004.06.004 · Cited by 73
Rogers, M. J., Watts, D. J., Russell, R. G. G., Ji, X., Xiong, X., Blackburn, G. M., Bayless, A. V., & Ebetino, F. H. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090710 · Cited by 73
Self-citationBody, J. (2004) · Seminars in Nephrology · doi:10.1053/j.semnephrol.2003.08.015 · Cited by 69
Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts
Murakami, H., Takahashi, N., Tanaka, S., et al. (1997) · Bone · doi:10.1016/s8756-3282(97)00025-2 · Cited by 69
Yamaguchi, T., Sugimoto, T., Yamauchi, M., Matsumori, Y., Tsutsumi, M., & Chihara, K. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0538-7 · Cited by 69
Rogers, M. J., Xiong, X., Ji, X., Mönkkönen, J., Russell, R. G. G., Williamson, M. P., Ebetino, F. H., & Watts, D. J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012157212793 · Cited by 68
Self-citationPapapoulos, S. E., Hoekman, K., Löwik, C. W. G. M., Vermeij, P., & Bijvoet, O. L. M. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040518 · Cited by 67
Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget’s Disease1
Singer, F. R., Clemens, T. L., Eusebio, R. A., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4871 · Cited by 66
Human protein tyrosine phosphatase-σ: Alternative splicing and inhibition by bisphosphonates
Endo, N., Rutledge, S. J., Opas, E. E., Vogel, R., Rodan, G. A., & Schmidt, A. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110415 · Cited by 59
Lalla, S., Hothorn, L. A., Haag, N., Bader, R., & Bauss, F. (1998) · Osteoporosis International · doi:10.1007/bf02672503 · Cited by 59
Lerner, U. H., & Larsson, Å. (1987) · Bone · doi:10.1016/8756-3282(87)90018-4 · Cited by 47
Bauss, F., Schenk, R., Hört, S., Müller‐Beckmann, B., & Sponer, G. (2004) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2003.11.003 · Cited by 46
Alendronate inhibition of protein-tyrosine-phosphatase-meg1
Opas, E. E., Rutledge, S. J., Golub, E. E., Stern, A. M., Zimoio, Z., Rodan, G. A., & Schmidt, A. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00225-6 · Cited by 36
Stutzer, A., Fleisch, H. A., & Trechsel, U. (1988) · Calcified Tissue International · doi:10.1007/bf02556639 · Cited by 32
Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget's Disease
Singer, F. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.6.1906 · Cited by 32
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Bell, R. H. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90001-8 · Cited by 23
Cited by
Role of Rab GTPases in Membrane Traffic and Cell Physiology
Hutagalung, A. H., & Novick, P. J. (2011) · Physiological Reviews · doi:10.1152/physrev.00059.2009 · Cited by 1,460
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro
Gentleman, E., Fredholm, Y. C., Jell, G., Lotfibakhshaiesh, N., O'Donnell, M. D., Hill, R. G., & Stevens, M. M. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.121 · Cited by 635
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Metadata
- Authors
- Russell, R. G. G.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2007-03-01
- Volume
- 119
- Issue
- Supplement_2
- Pages
- S150-S162
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2163048481
- Cited by
- 503
- References
- 141
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.